<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="HF720E50C50FA4EE1B4EB2DF5C59EDECF" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>118 HR 1350 IH: Cameron’s Law</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2023-03-03</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">118th CONGRESS</congress><session display="yes">1st Session</session><legis-num display="yes">H. R. 1350</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20230303">March 3, 2023</action-date><action-desc><sponsor name-id="G000583">Mr. Gottheimer</sponsor> (for himself and <cosponsor name-id="B001298">Mr. Bacon</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HWM00">Committee on Ways and Means</committee-name>, and in addition to the Committee on <committee-name committee-id="HIF00">Energy and Commerce</committee-name>, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned</action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To amend the Internal Revenue Code of 1986 to restore the amount of the orphan drug tax credit, and for other purposes.</official-title></form><legis-body id="HAB8A1AEF27D6412B8FF788F627680A71" style="OLC"><section id="H97FA94F0357D4C2CB4F691B0CB9B1F05" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as <quote><short-title>Cameron’s Law</short-title></quote>. </text></section><section id="HCD73F776CF7A451883BCC6EFDB6FDD79"><enum>2.</enum><header>Restoration of amount of orphan drug tax credit</header><subsection id="H6437297B92E24DA186E774F4E270058F"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline"><external-xref legal-doc="usc" parsable-cite="usc/26/45C">Section 45C(a)</external-xref> of the Internal Revenue Code of 1986 is amended by striking <quote>25 percent</quote> and inserting <quote>50 percent</quote>.</text></subsection><subsection id="H8A6D6A0D8B834673ADF57FBA31593ACF"><enum>(b)</enum><header>Effective date</header><text display-inline="yes-display-inline">The amendment made by this section shall apply to taxable years beginning after the date of the enactment of this Act.</text></subsection></section><section id="H4A7CF8AD255A4B3C8225B0CC752E5C67"><enum>3.</enum><header>CDC feasibility study on surveillance infrastructure for rare diseases and conditions</header><subsection id="HC6F7BD781303453BAD57181E24F0A5C0"><enum>(a)</enum><header>Study</header><text display-inline="yes-display-inline">Not later than 1 year after the date of enactment of this Act, the Director of the Centers for Disease Control and Prevention (in this section referred to as the <quote>Director</quote>) shall complete a study to evaluate the feasibility of enhancing and expanding the infrastructure to track the epidemiology of rare diseases and conditions, including with respect to the following:</text><paragraph id="H854CFE10320C4731B222A2469253D482"><enum>(1)</enum><text>Rates of mortality.</text></paragraph><paragraph id="H1B158911FAD64F47BA84DB51D27581FB"><enum>(2)</enum><text>Potential for research and treatment.</text></paragraph><paragraph id="H4D8D5DAF9B654DFA9924B5399FE9C386"><enum>(3)</enum><text>Demographics.</text></paragraph><paragraph id="HB046B8AF21654DB9880A4949F0E6F798"><enum>(4)</enum><text>Diagnosis and progression markers.</text></paragraph><paragraph id="H8EB70D6549F343919596E76D8E9C54EF"><enum>(5)</enum><text>The history of the disease or condition.</text></paragraph><paragraph id="H184C6576F72741E89FF4683423128ACC"><enum>(6)</enum><text>Detection management.</text></paragraph></subsection><subsection id="HA8217F043F1F4D1C95CE6670CEE3EB5D"><enum>(b)</enum><header>Consultation</header><text>In conducting the study required by subsection (a), the Director shall consult with relevant experts, including—</text><paragraph id="H4B0DD7361B7F4AC29F77865D729EC305"><enum>(1)</enum><text>epidemiologists with experience in disease surveillance;</text></paragraph><paragraph id="HF0988BE393B647359F9D431F3C3D7AAE"><enum>(2)</enum><text>representatives of national voluntary health associations;</text></paragraph><paragraph id="H57D84A092FDA4ECF87D27C497675FDBB"><enum>(3)</enum><text>health information technology experts or other information management specialists;</text></paragraph><paragraph id="H05F56BE2107E4D2F880E70562CF076C9"><enum>(4)</enum><text>clinicians with expertise in rare diseases or conditions;</text></paragraph><paragraph id="HC5BD85B834F948A79E574A15514EE381"><enum>(5)</enum><text>research scientists with expertise in rare diseases or conditions, or experience conducting translational research or utilizing surveillance systems for scientific research purposes; and</text></paragraph><paragraph id="H677413A1B2234F4F8278C4E2E62DA3EA"><enum>(6)</enum><text>patients, and caregivers of patients, with rare diseases or conditions.</text></paragraph></subsection><subsection id="HAA44A9A8F49248BF9B2DC8E36A6E5C4A"><enum>(c)</enum><header>Report</header><text>Not later than 3 months after completing the study required by subsection (a), the Director shall submit a report to the Congress on the results of the study.</text></subsection><subsection id="HF32AEB7275E9479C98119B62DA3A9DBB"><enum>(d)</enum><header>Definition</header><text>In this section, the terms <term>rare diseases and conditions</term> and <term>rare diseases or conditions</term> refer to human diseases and conditions that are—</text><paragraph id="H869A8E0BF1CC4827ACED51E9D2DA2D4E"><enum>(1)</enum><text>a rare disease or condition, as defined in section 526 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360bb">21 U.S.C. 360bb</external-xref>); or</text></paragraph><paragraph id="H434CDE0692F949B1BC36918E14AA39E1"><enum>(2)</enum><text>determined by the Director to be rare and lacking in treatment options, so as to warrant consideration in the study required by subsection (a).</text></paragraph></subsection></section></legis-body></bill> 

